Winston Smith Massmierda REESCRIBIENDO EL PASADO del TimoSIDA:"En año 90 no había medicación".Letal

Hi-Five dijo:

Infantil y falaz es, que de los múltiples parágrafos y referencias que he puesto los reduzcas a una línea -ignorando el resto- para que no se te desmonte tal falsedad.

Lee, lee el resto que has ignorado deliberadamente, el porqué el AZT ni los demás antiretrovirales no pueden causar el SIDA:

Hacer clic para expandir...

Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinati... - PubMed - NCBI

The 3-year estimated survival probabilities were 92% (95% CI 90-94%) in Imm and 94% (92-95%) in Def (log-rank p = 0.13), with no significant differences overall or in subgroup analyses by CD4 cell count at baseline. Similarly, there was no significant difference in progression of HIV disease: 3-year progression rates to AIDS or death were 18% in both groups, and to ARC, AIDS, or death were 29% (Imm) and 32% (Def) (p = 0.18)

Hacer clic para expandir...

Hi-Five dijo:

Infantil y falaz es, que de los múltiples parágrafos y referencias que he puesto los reduzcas a una línea -ignorando el resto- para que no se te desmonte tal falsedad.

Lee, lee el resto que has ignorado deliberadamente, el porqué el AZT ni los demás antiretrovirales no pueden causar el SIDA:

Hacer clic para expandir...

AYN RANDiano2 dijo:

Ay, señor mío, ignora usted por lo que veo el ESTUDIO CONCORDE, que desmiente a sus mentirosísimas fuentes oficialistas:

concorde study azt - Buscar con Google
Cito:
El grupo Def (Deferred) tienen MENOS mortalidad.
A todo esto, ¿dónde estan los estudios CON ANIMALES de los efectos del AZT?

ADICIONALMENTE: EL VADEMECUM.


Le leo el vademecum para que salga usted de su ignorancia:

Reacciones adversas:
Para muchas de ellas no está claro si están relacionadas con lamivudina, zidovudina o con la amplia serie de fármacos utilizados en el control de la enfermedad causada por el VIH o si son consecuencia de la enfermedad subyacente​

combivir "no está claro si están relacionadas" - Buscar con Google
El mismo fabricante del AZT advierte en el prospecto que sus "reacciones adversas" le son indistinguibles de los supuestos efectos de la supuesta "infección por VIH".

Le desmienten a usted...los fabricantes de AZT, que en el prospecto al menos cuentan la triste verdad.

Hacer clic para expandir...

there was no statistically significant difference in clinical outcome between the two therapeutic policies. The 3-year estimated survival probabilities were 92% (95% CI 90-94%) in Imm and 94% (92-95%) in Def (log-rank p = 0.13), with no significant differences overall or in subgroup analyses by CD4 cell count at baseline. Similarly, there was no significant difference in progression of HIV disease: 3-year progression rates to AIDS or death were 18% in both groups, and to ARC, AIDS, or death were 29% (Imm) and 32% (Def) (p = 0.18), although there was an indication of an early but tras*ient clinical benefit in favour of Imm in progression to ARC, AIDS, or death. However, there was a clear difference in changes in CD4 cell count over time in the two groups

Hacer clic para expandir...

Original treatment groups included placebo, 500 mg of zidovudine, or 1500 mg of zidovudine
During ***ow-up of up to 4.5 years (miccionan, 2.6 years), 232 subjects progressed to AIDS or died. In each of the three analyses described herein, zidovudine was associated with a significant (P = .008, .004, .007) decrease in the risk of such progression.

Hacer clic para expandir...

In a double-blind, placebo-controlled trial, 993 patients with asymptomatic HIV infection and CD4+ cell counts above 400 per cubic millimeter were randomly assigned to receive zidovudine (500 mg twice daily) or placebo for three years.
Disease progression was significantly less frequent in the zidovudine group (relative risk, 0.56; 95 percent confidence interval, 0.43 to 0.75; P < 0.001 by the log-rank test). The probability of disease progression at two years was 0.19 with zidovudine, as compared with 0.34 with placebo (95 percent confidence interval for the difference, -0.21 to -0.08). Progression to CDC group IV disease was reduced by half in the zidovudine recipients (relative risk, 0.49; P = 0.049) and decline in CD4+ cell counts to below 350 per cubic millimeter was reduced by 40 percent (relative risk, 0.60; P < 0.001).
Despite the use of doses larger than those now generally prescribed, zidovudine was well tolerated for up to three years by most of our patients.

Hacer clic para expandir...

HIV-infected individuals treated with zidovudine had significantly reduced mortality and progression to AIDS for ***ow-up intervals of six, 12, 18 and 24 months compared to those not taking zidovudine, even after adjusting for health status, CD4+ T cell counts and PCP prophylaxis

Hacer clic para expandir...